• H. Herrschaft


1 mg Wirkstoff besteht aus: 0,33 mg Dihydroergocorninmethansulfonat, 0,33 mg Dihydroergocristinmethansulfonat, 0,22 mg Dihydro-Alpha-ergocryptinmethansulfonat, 0,11 mg Dihydro-Beta-ergocryptinmethansulfonat.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aellig WH, Nüesch E (1977) Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 15: 106–112Google Scholar
  2. Arrigo A, Braun P, Kauchtschischwili GM (1973) Influence of treatment on symptomatology and correlated electroencephalographic (EEG) changes in the aged. Clin Ther Res 15: 417–426Google Scholar
  3. Baldy-Moulinier M, Daprès G, Passouant P (1969) Organization of sleeping and waking in the cat during the 24 hours: pharmacological changes. Electroencephalogr Clin Neurophysiol 27: 105PubMedGoogle Scholar
  4. Banen DM (1972) An ergot preparation (Hydergine) for relief of symptoms of cerebrovascular insuffiency. J Am Geriatr Soc 20: 22–24PubMedGoogle Scholar
  5. Bargheon J (1973) Double-blind study of hydergine in geriatric patients. Nouv Presse Med 2: 2053–2055PubMedGoogle Scholar
  6. Barnhard PJ (1961) Centr Afr J Med 7: 355–360 (zit. nach WEIL 1988)Google Scholar
  7. Bazo AJ (1973) An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double-blind study. J Am Geriatr Soc 21: 63–71PubMedGoogle Scholar
  8. Berde B (1972) Some new vascular and biochemical aspects of the mechanism of action of ergot compounds. Headache 11: 139–147PubMedGoogle Scholar
  9. Bertoni-Freddari C, Giuli C, Pieri C, Paci D (1986) Quantitative investigation of the morphological plasticity of synaptic junctions in rat dentate gyrus during aging. Brain Res 366: 187–192PubMedGoogle Scholar
  10. Bertoni-Freddari C, Giuli C, Pieri C et al. (1987) The effect of chronic Hydergine treatment on the plasticity of synaptic junctions in the denate gyrus of aged rats. J Gerontol 42: 482–486PubMedGoogle Scholar
  11. Biel ML, Seus R, Struppler A (1976) Medikamentöse Therapie des hirnorganischen Psychosyndroms im Alter. Med Klin 71: 2177–2189PubMedGoogle Scholar
  12. Bluntschli HJ, Goetz RH (1947) The effect of a new sympathicolytic drug (Dihydroergocornine) on the blood-pressure with special reference to hypertension. S Afr Med J 11: 382Google Scholar
  13. Bock KD, Welzel D, Dennler HJ (1982) Co-Dergocrinemesylat bei älteren Hypertonikern (therapeutische Mitteilung). Münch Med Wochenschr 124: 1095–1098Google Scholar
  14. Breeze RW, Cox S, Rodgers-Coxj (1988) Changes in P-300 latency as a result of co-dergocrine mesylate therapy in patients with senile dementia. Int J Geriatr Psychiat 3: 263–266Google Scholar
  15. Cerletti A, Emmenegger H, Enz A, Iwangoff P, Meier-Ruge W (1973) Effects of ergot DH-alkaloids on the metabolism and function of the brain. An approach based on studies with DH-Ergonine. In: Genazzani E, Herken H (eds) Centr Nerv Stud on Metab Regul and Funct. Springer, Berlin Heidelberg New York, pp 201–212Google Scholar
  16. Chien C, Marder SR, Van Putten T, Escobar J (1980) In: Collegium Internationale Neuropsychopharmacologicum. Prog Neuropsychopharmacol 1: 105–106Google Scholar
  17. Chierichetti S, Cucinotta D, Santini V (1985) In: Gaitz CM, Samorajski T (eds) Ageing 2000: our health care destiny, vol I. Springer, Berlin Heidelberg New York Tokyo, pp 377–393Google Scholar
  18. Closse A, Frick W, Dravid A et al. (1984) Classification of drugs according to receptor profiles. Naunyn Schmiedebergs Arch Pharmacol 327: 95–101PubMedGoogle Scholar
  19. Cole JO (1980) Drug therapy of senile organic drug syndromes. Psychiat J Univ Ottawa 5:41–52Google Scholar
  20. Cox JR, Pandurangi VR, Wallace MG (1978) Drugs will help if dementing patients are caught early. Mod Geriatr 8: 12, 14–15Google Scholar
  21. Cripps H, Dearnaley DP (1972) Vascular responses and noradrenaline overflows in the isolated blood-perfused cat spleen: some effects of cocaine, normetanephrine and a-blocking agents. J Physiol 227: 647–664PubMedGoogle Scholar
  22. Ditch M, Kelly FJ, Resnick O (1971) An ergot preparation (Hydergine) in the treatment of cerebrovascular disorders in the geriatric patient: a double-blind study. J Am Geriatr Soc 19: 208–217PubMedGoogle Scholar
  23. Dominiak P, Weidinger G (1983) Therapie der isolierten systolischen Hypertonie im Alter. Med Klin 78: 536–539Google Scholar
  24. Dravid AR, Hiestand P (1985) Deficit des activités enzymatiques cholinergiques dans les zones septo-temporales de l’hyppocampe de rat age et dans le cerveau antérieur de souris agée. Action du traitement par l’hydergine. J Pharmacol 16[Suppl III]: 29–37Google Scholar
  25. Ehrly AM, Saeger-Lorenz K (1992) Beeinflussung der Erythrozyten-Verformbarkeit hyperosmolaren Blutes in vitro durch Co-Dergocrinmesilat. Arzneimitteimittelforschung/Drug Res 42: 1009–1011Google Scholar
  26. Einspruch BC (1976) Helping to make the final years meaningful for the elderly residents of nursing homes. Dis Nerv Syst 37: 439–442PubMedGoogle Scholar
  27. Elwan O, Helmy AA, Tamawy ME, Naseer MA, Banhawy IE, Kader AAA, Elwan F (1995) Er-goloids and ischaemic strokes. Efficacy and mechanism of action. J Int Res 23: 154–166Google Scholar
  28. Emmenegger H, Meier-Ruge W (1968) The actions of Hydergine on the brain. A histochemical, circulatory and neurophysiological study. Pharmacology 1: 65–78PubMedGoogle Scholar
  29. Fanchamps A (1979) Controlled studies with dihydroergotoxine in senile cerebral insufficiency. In: Nandy K (ed) Geriatric psychopharmacology. Elsevier North-Holland, New York, pp 195–212Google Scholar
  30. Fanchamps A (1983) Dihydroergotoxine in senile cerebral insufficiency. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 311–322 (Aging, vol 23)Google Scholar
  31. Flückinger E, Balthasar HU (1967) Dihydroergocristin: Unterschiedliche Wirkungen an venösem und arteriellem Gewebe. Arzneimittelforschung /Drug Res 17: 6–9Google Scholar
  32. Freis ED, Stanton JR, Wilkins RW (1948) The effects of certain dihydrogenated alkaloids of ergot in hypertensive patients. Am J Med Sci 216: 163PubMedGoogle Scholar
  33. Gaddum JA, Paasonen MKV (1955) Br J Pharmacol 10: 474–483 (zit nach WEIL 1988)Google Scholar
  34. Gaitz CM, Varner RV (1974) Pharmacotherapy of late life organic brain syndromes; evaluation of Hydergine (an ergot derivative) versus placebo using double-blind technique. Gerontologist 14: 44Google Scholar
  35. Gaitz CM, Hartford JT (1979) Ergot alkaloids in treatment of geriatric patients with dementia. In: Nandy K (ed) Geriatric psychopharmacology. Elsevier North-Holland, New York, pp 213–224Google Scholar
  36. Gaitz CM, Varner RV, Overall JE (1977) Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry 34: 839–845PubMedGoogle Scholar
  37. Gherondache DN (1977) Data on file at Sandoz Inc, East Hanover, NJ, USAGoogle Scholar
  38. Goldstein M (1985) Ergot alkaloids and central monoaminergic receptors. J Pharmacol (Paris) 16 [SupplIII]: 19–24Google Scholar
  39. Goldstien M, Lew JY, Hata F, Lieberman A (1978) Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 24 [Suppl I]: 76–85Google Scholar
  40. Gomez E (1977) Clinical observations in the treatment of tardive dyskinesia with dihydrogenated ergot alkaloids (Hydergine). Preliminary findings. Psychiat J Univ Ottawa 2: 67–71Google Scholar
  41. Grabner W, Weidinger G (1982) Behandlung der Hypertonie im Alter. Med Klin 77: 694–698Google Scholar
  42. Grauwiler J, Schoen H (1973) Teratological experiments with ergotamine in mice, rats and rabbits. Teratology 7: 227–235Google Scholar
  43. Griffith RW, Grauwiler J, Hodel C, Leist KH, Matter B (1978) Ergot alkaloids and related compounds. In: Berde B, Schild HO (eds) Handbuch der experimentellen Pharmakologie, vol 49. Springer, Berlin Heidelberg New York, S 805–851Google Scholar
  44. Guffanti E, Vaccarella A, Meregalli M, Fiorella G, Chierichetti SM, Mazzola C (1985) A single blind comparison of dihydroegotoxine mesilate and Clonidine for treatment of hypertensive emergencies. Int J Clin Pharmacol Ther Toxicol 23: 506–509PubMedGoogle Scholar
  45. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R (1982) Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires. Rev Neurol (Paris) 138: 367–385Google Scholar
  46. Gygax P, Meier-Ruge W, Schulz U, Enz A (1976) Proceedings: experimental studies on the action of metabolic and vasoactive substances in the oligemically disturbed brain. Arzneimittelforschung /Drug Res 26: 1245–1246Google Scholar
  47. Hajioff J, Wallace MG (1982) Treatment of tardive dyskinesia with Co-Dergocrine mesylate. Br J Clin Pract 16: 43–46Google Scholar
  48. Hariri NI, Falakali B, Algan O (1992) The effects of Hydergine on the synaptic plasticity of aged rats. Clin Neuropharmacol 15 [PB Suppl 1]: 560B (Abs P-123-640)Google Scholar
  49. Heiss R, Seus R, Fahrenberg J (1971) Eine Studie zur Prüfung der psychodynamischen Wirkung von Dihydroergotoxin. Arzneimittelforschung /Drug Res 21: 797–800Google Scholar
  50. Herzfeld U, Christian W, Oswald WD et al. (1972) Zur Wirkungsanalyse von Hydergin im Langzeitversuch. Eine interdisziplinäre Studie. Med Klin 67: 1118–1125PubMedGoogle Scholar
  51. Heuer LJ, Anders T (1983) Behandlung der Hochdruckkrise mit Hydergin. Med Klin 78: 564–566Google Scholar
  52. Hollingsworth SW (1974) Effective nursing home care for elderly patients. Evaluation and treatment. Scient Exhibit Am Med Assoc Clin Convention, Portland, OregonGoogle Scholar
  53. Hollingsworth SW (1980) Response of geriatric patients from the satellite nursing homes of Maricopa County to Hydergine therapy, a double-blind study. Curr Ther Res 27:401–410Google Scholar
  54. Horowski R, Mc Donald RJ (1983) Experimental and clinical aspects of ergot derivatives used in the treatment of age-related disorders. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 283–303 (Aging, vol 23)Google Scholar
  55. Horsch A (1982) Prüfung der blutdrucksenkenden Wirkung von Hydergin speziell unter stationären Bedingungen. Therapiewoche 32: 3882–3886Google Scholar
  56. Huber F, Köberle S, Prestele H, Spiegel R (1986) Effects of long-term ergoloid mesylates („Hydergine“ ) administration in healthy pensioniers: 5-year results. Curr Med Res Opin 10: 256–279PubMedGoogle Scholar
  57. Hughes JR, Williams JG, Currier RA (1976) An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc 24:490–497PubMedGoogle Scholar
  58. Humbert H, Lavene D, Guillaume MF, Kiechel JR (1975) Pharmacokinetics and bioavailability with two ergot peptide alkaloids: co-dergocrine and dihydroergotamine. In: Gershon S, Raskin A (eds) Genesis and treatment of psychologic disorders in the elderly. Raven Press, New York, pp 334–340 (Aging, vol 2)Google Scholar
  59. Humbert H, Lavène D, Guillaume MF, Kiechel JK (1981) In: Aiache JM, Hirtz J (eds) 1er Congrès Européen de Biopharmacie et de Pharmacocinétique. Technique et Documentation, Paris, pp 334–340Google Scholar
  60. Hunziker O, Emmenegger H, Meier-Ruge W, Schulz U (1974) The behaviour of morphometry parameters of cortical capillaries in the cat’s brain influenced by DH-ergotoxine and papaverine. Int Res Commun Syst Med Sci 2: 1481–1489Google Scholar
  61. Iwangoff P, Enz A, Chappuis A (1975) Inhibition of cAMP-phosphodiesterase of different cat organs by DH-ergotoxine in the micromolar substrate range. Int Res Commun Syst Med Sci 3: 403–406Google Scholar
  62. Iwangoff P, Meier-Ruge W, Schieweck C, Enz A (1976) The uptake of DH-ergotoxine by different parts of the cat brain. Pharmacology 14: 27–38PubMedGoogle Scholar
  63. Jennings WC (1972) An ergot alkaloid preparation (Hydergine) versus placebo for treatment of symptoms of cerebrovascular insufficiency: double-blind study. J Am Geriatr Soc 20: 407–412PubMedGoogle Scholar
  64. Kappert A, Baumgartner P, Rupp F (1948) über die blutdrucksenkende Wirkung neuer hydrierter Mutterkornalkaloide. Schweiz Med Wochenschr 78: 1265PubMedGoogle Scholar
  65. Kawashima K, Kogure K, Ido T, Itoh M, Hatazawa J (1988) Increase in cerebral metabolic rate of glucose in multi-infarct dementia following intravenous administration of co-dergocrine mesylate (Hydergine). Neurol 235 [Suppl]: 1Google Scholar
  66. Koeberle S, Spiegel R (1984) A long-term study with Co-Dergocrine mesylate (Hydergine) in healthy pensioners. Result after 3 years. Gerontology 30[Suppl 1]: 3–52Google Scholar
  67. Kugler J, Oswald WD, Herzfeld U et al. (1978) Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103: 456–462PubMedGoogle Scholar
  68. Lancranjan I (1983) New perspectives in the treatment of tardive dyskinesia with dihydroergotoxine. In: Agnoli A, Crepaldi C, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 329–338 (Aging, vol 23)Google Scholar
  69. Lavène D, Humbert H, Kiechel JR et al. (1985) Hydergine pharmacokinetics in the elderly. J Pharmacol (Paris) 16 [Suppl III]: 57–63Google Scholar
  70. Le Poncin-Lafitte M, Rapin JR, Duterte D (1985) Learning and cholinergic neurotransmission in old animals: the effect of Hydergine. J Pharmacol (Paris) 16 [Suppl III]: 57–63Google Scholar
  71. Linden ME (1975) Retirement and the elderly patient: problems and practical therapy. Scientific exhibit; 1-19 Am Geriatr Soc, 124th Annual MeetingGoogle Scholar
  72. Loew DM, Vigouret JM, Jaton AL (1976a) Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine. Postgrad Med J 52[Suppl 1]: 40–46PubMedGoogle Scholar
  73. Loew DM, Deporteere H, Bürki HR (1976b) Effects of dihydrogenated ergot alkaloids on the sleep wakefulness cycle and on brain biogenic amines in the rat. Arzneimittelforschung/ Drug Res 26: 1080–1083Google Scholar
  74. London ED, Walovitch RC (1985) Cerebral glucose metabolism in aging rodents: effects of co-dergocrine. J Pharmacol (Paris) 16[Suppl III]: 73–84Google Scholar
  75. Markstein R (1985) Hydergine: interaction with neurotransmitter systems in the central nervous system. J Pharmacol (Paris) 16[Suppl III]: 1–7Google Scholar
  76. Markstein R, Wagner H (1978) Effects of dihydroergotoxine on cyclic AMP generating systems in rat cerebral cortex slices. Gerontology 24[Suppl 1]: 94–105PubMedGoogle Scholar
  77. Markstein R, Closse A, Frick W (1983) Interaction of ergot alkaloids and their combination (co-dergocrine) with a-adrenoceptors in the CNS. Eur J Pharmacol 93: 156–169Google Scholar
  78. Matejcek M (1983) EEG of the aging brain. Contribution of quantitative electroencephalography to geriatric research: application with er-goloid mesylates. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 97–103 (Aging, vol 23)Google Scholar
  79. Matejcek M, Knor K, Piguet PV, Weil C (1979) Electroencephalographic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation. J Am Geriatr Soc 27: 198–202PubMedGoogle Scholar
  80. Matter BE, Grauwiler J (1975) The micronucleus test as a simple model, in vivo, for the evaluation of drug — induced chromosome aberrations. Comparative studies with 13 compounds. Mut Res 29: 198–199Google Scholar
  81. Matter BE, Tsuchimoto T, Deyssenroth H (1978) Failure to detect dominant — lethal mutations and effects on reproductive capacity in mice exposed to dihydroergotoxine mesylate. Arzneimittelforschung Drug Res 28: 2286–2290Google Scholar
  82. Mc Connachie RW (1973) A clinical trial comparing Hydergine with placebo in the treatment of cerebrovascular insufficiency in elderly patients. Curr Med Res Opin 1: 463–468Google Scholar
  83. Mc Donald RJ (1979) Hydergine: a review of 26 clinical studies. Pharmacopsychiatry 12: 407–422Google Scholar
  84. Meier Ruge W (1986) Effects of prolonged co-dergocrine mesylate (Hydergine) treatment on local cerebral glucose uptake in aged Fischer 344 rats. Arch Gerontol Geriatr 5: 65–77PubMedGoogle Scholar
  85. Meier Ruge W, Enz A, Gygax P et al. (1975) Experimental pathology in basic research of the aging brain. In: Gershon S, Raskin A (eds) Genesis and treatment of psychologic disorders in the elderly. Raven Press, New York, pp 55–126 (Aging, vol 2)Google Scholar
  86. Mémin Y, Najean Heuber E (1973) Etude à double insu selon une échelle d’appréciation quantitative d’un traitement des troubles vasculaires cérébraux chroniques. Sem Hôp (Paris) 49: 605–608Google Scholar
  87. Moglia A, Bono G, Sinforiani E, Alffonsi E, Zandrini C, Pistarini C, Arrigo A, Franch F (1983) Farmaco (ed prat) 38: 97–102Google Scholar
  88. Nagasawa H, Kogure K, Kawashima T et al. (1989) Influence of Hydergine on brain cell metabolism as demonstrated by PET. In: Carlsson A, Kanowski S, Allain H, Spiegel R (eds) Cerebral insufficiency. Trends in research and treatment, vol 1–4. Parthenon Publishing Group, Carnforth (UK) and Park Ridge (USA), vol 3, pp 169–178Google Scholar
  89. Nelson JJ (1975) Relieving selected symptoms of the elderly. Geriatrics 30: 133–142PubMedGoogle Scholar
  90. Ogawa N, Nomura M, Haba K, Asanuma M, Tanaka K, Hori K, Mori A (1992) Effects of dihydroergotoxine on central cholinergic neuronal systems and discrimination learning test in aged rats. Brain Res 586: 229–234PubMedGoogle Scholar
  91. Orth OA, Capps RA, Suckle HM (1947) Some pharmacological properties of dihydroergocornine (DHO 180). Fed Proc 6: 361PubMedGoogle Scholar
  92. Oswald WD, Lang E (1980) Therapeutische Beeinflussung von Leistung und Selbstbild bei geriatrischen Patienten. Münch Med Wochenschr 122: 59–62Google Scholar
  93. Oswald WD, Matejcek M, Lukaschek K (1982) über die Relevanz psychometrisch operatio-nalisierter Therapie-Effekte bei der Behandlung altersbedingter Insuffizienzerscheinungen des Gehirns als Beispiel des Nürnberger-Alters-Inventars. Arzneimittelforschung/Drug Res 32: 584–590Google Scholar
  94. Rao DB, Norris JR (1972) A double-blind investigation of hydergine in the treatment of cerebrovascular insufficiency in the elderly. Johns Hopk Med J 130: 317–324Google Scholar
  95. Rehman SA (1973) Two trials comparing Hydergine with placebo in the treatment of patients suffering from cerebrovascular insufficiency. Curr Med Res Opin 1: 456–462PubMedGoogle Scholar
  96. Roberts GT, Rand MJ (1977) Effects of some ergot dérivates in bone marrow of mice. Mutat Res 56: 59–67PubMedGoogle Scholar
  97. Rodriguez JM (1973) A double-blind placebo controlled study of Hydergine in the treatment of cerebrovascular insufficiency in the elderly. Data on file at Sandoz Ine, East Hanover, NJ, USAGoogle Scholar
  98. Rosen HJ (1975) Mental decline in the elderly: pharmacotherapy (ergot alkaloids versus papaverine). J Am Geriatr Soc 23: 169–174PubMedGoogle Scholar
  99. Rothlin E, Bruegger J (1945) Quantitative Untersuchungen der sympathikolytischen Wirkung genuiner Mutterkornalkaloide und derer Dihydroderivate am isolierten Uterus des Kaninchens. Helv Physiol Acta 3: 519Google Scholar
  100. Rothlin E, Cerletti A (1949) Pharmakologie des Hochdrucks. Verh Dtsch Ges Kreisl Forsch 15: 158Google Scholar
  101. Roubicek J, Geiger C, Abt K (1972) An ergot alkaloid preparation (hydergine) in geriatric therapy. J Am Geriatr Soc 20: 222–229PubMedGoogle Scholar
  102. Rouy JM, Douillon AM, Compan B (1986) L’Hydergine dans le traitement de la détérioration intellectuelle du sujet agé. Résultats d’un essai à double insu d’une durée de 6 mois. Trib Méd 200: 69–74Google Scholar
  103. Ruether E, Welzel D, Dennler HJ, Dunkl E, Kazenwadel J, Kohnen R, Krueger HP, Sommer H (1993) Infusion therapy with Hydergin in older patients with a mild to moderate organic brain syndrome. Pharmacopsychiatry 26 (Spec Issue): 192Google Scholar
  104. Saletu B, Gruenberger J, Anderer P, Linzmayer L, Pakesch G, Zyhlarz G (1994) Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard and Hydergine) by EEG mapping and psychometry under hypoxia. Arch Gerontol Geriatr 18: 81–99PubMedGoogle Scholar
  105. Salzmann R, Pacha W (1976) The effects of ergot compound on the release of noradrenaline and prostaglandins from the isolated perfused cat spleen during nerve stimulation. Postgrad Med J 52[Suppl 1]: 24–31PubMedGoogle Scholar
  106. Schneider LS, Olin JT (1994) Overview of clinical trials of hydergine in dementia. Arch Neurol 51: 787–798PubMedGoogle Scholar
  107. Segre G, Bruni B, Dal Pra P et al. (1983) Pharmacokinetic analysis: new methods and results with ergot alkaloids. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 395–406 (Aging, vol 23)Google Scholar
  108. Singer JM, Harnot HB, Patin JR (1985) Differential patient response to ergoloid mesylates according to current etiopathic notions of dementia. In: Gaitz CM, Samorajski T (eds) Aging 2000: our health care destiny. Springer, New York, pp 405–420 (Biochemical issues, vol 1)Google Scholar
  109. Smith JA, Zalman S (1949) Prac Soc Ep Biol (NY) 72: 13–15Google Scholar
  110. Sörgel F, Abisch E, Dennler HJ, Lang E (1984) Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients. Eur Clin Pharmacol 26: 133–135Google Scholar
  111. Spilich GJ, Wannenmacher W, Duarte A, Buendia R, Gomez JT, Ramirez S, Anaya A, Otero E (1996) Efficacy of pyritinol versus hydergine upon cognitive performance in patients with senile dementia of the Alzheimer’s type: a double-blind multi-center trial. Alzheimer’s Res 2: 79–84Google Scholar
  112. Stewart RB, Marks RG, Caranasos GC, Hale WE (1996) Prevalence of ergoloid mesylate use in an ambulatory elderly population over a 14 year period. J Geriatr Drug Ther 10: 63–72Google Scholar
  113. Susic V, Masirevic G (1979) Effects of dihydroergotoxine (Hydergine) on the sleep-wakefulness cycle the cat. Gerontology 25: 212–218PubMedGoogle Scholar
  114. Tanaka K, Ogawa N, Asanuma M, Hirata H, Kondo Y, Chou H, Mori A (1992) Effects of chronic codergocrine mesylate administration on the brain somatostatinergic system in aged rats. Arch Gerontol Geriatr 15: 133–139PubMedGoogle Scholar
  115. Thibault A (1974) A double-blind evaluation of „Hydergine“ and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Curr Med Res Opin 2: 482–487PubMedGoogle Scholar
  116. Thienhaus OJ, Wheeler BG, Simons S et al. (1987) A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. J Am Geriatr Soc 35: 219–223PubMedGoogle Scholar
  117. Triboletti F, Ferri H (1969) Hydergine for treatment of symptoms of cerebrovascular insufficiency. Curr Ther Res 11: 609–620PubMedGoogle Scholar
  118. Ulmar G, Schmidt-Zedler C (1993) Zur klinischen Effizienz nootropischer Behandlung bei fortgeschrittenen Demenzen. Ein Therapievergleich der psychiatrischen Krankenhaeuser in Marburg und Gießen. Krankenhauspsychiatrie 4: 106–111Google Scholar
  119. Venn RD (1978) Clinical pharmacology of ergot alkaloids in senile cerebral insufficiency. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, pp 533–566 (Handb Exp Pharmacol, vol 49)Google Scholar
  120. Vigouret JM, Burki HR, Jaton AL et al. (1978) Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712. Pharmacology 16 [Suppl 1]: 156–173PubMedGoogle Scholar
  121. Wadworth AN, Chrisp P (1992) Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs and Aging 2: 153–173PubMedGoogle Scholar
  122. Weil C (1988) Hydergine: pharmacologic and clinic facts. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  123. Wennmalm A (1971) Quantitative evaluation of release and reuptake of adrenergic transmitter in the rabbit heart. Acta Physiol Scand 82: 532–538PubMedGoogle Scholar
  124. Weth G (1982) Zur Behandlung der hypertonen Krise mit Hydergin. Z Allg Med 58: 1366–1368Google Scholar
  125. Wiernsperger N, Gygax P, Danzeisen M (1978) Cortical pO2-distribution during oligemic hypotension and its pharmacological modifications. Arzneimittelforschung/Drug Res 28: 768–770Google Scholar
  126. Wilder BJ, Gonyea EF (1973) The effects of the dihydrogenated ergot alkaloids on symptoms of aging: a controlled pilot study of clinical neurologic and EEG changes. Scientific exhibit. Am Med Ass Annu Convention, New York, June 23–27Google Scholar
  127. Winslow IE (1974) The hospitalized geriatric patient: guidelines for effective therapy. Scientific exhibit: 1–24. Am Med Assoc Meeting, Portland, Nov 30-Dec 3Google Scholar
  128. Wright AM, Morrehead M, Welsh JH (1962) Br J Pharmacol 18: 440–450Google Scholar
  129. Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA (1979) Vasodilators in senile dementias: a review of the literature. Arch Gen Psychiatry 36: 220–223PubMedGoogle Scholar
  130. Yesavage JA, Westphal J, Rush L (1981) Senile dementia: combined pharmacologic and psychologic treatment. J Am Geriatr Soc 29: 164–174PubMedGoogle Scholar
  131. Züger PE, Vigouret JM, Loew DM (1978) Inhibition of reserpine-induced PGO-spikes in the cat by ergot derivatives. Experientia 34: 637–639PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • H. Herrschaft

There are no affiliations available

Personalised recommendations